A New Audio Interview Featuring Nadav Kidron, CEO of Oramed, is Now at SmallCapVoice.com and Somaxon Pharmaceuticals Announces Silenor Co-Promotion Agreement with Procter & Gamble

Share: 

City of Industry, CA --(www.USEquityNews.com)-- 08/25/2010 - Pharmaceutical industry alert provided by U.S. Equity News. SmallCapVoice.com, Inc. announced today that a new audio interview featuring Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (http://www.oramed.com), a developer of oral delivery systems, is now available. The interview can be heard at http://smallcapvoice.com/blog/8-24-10-audio-interview-with-oramed-pharmaceuticals-inc-otcbb-ormp.


SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and company information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.

Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that Somaxon and Procter & Gamble (NYSE: PG) have entered into a co-promotion agreement for Silenor(R) (doxepin), a newly-approved treatment for insomnia characterized by difficulty with sleep maintenance.

Under the terms of the agreement, Somaxon and Procter & Gamble will co-promote Silenor with a combined 215 sales representatives in the U.S. market. Procter & Gamble's professional health care sales force will promote Silenor to targeted primary care and other high-prescribing physicians. Somaxon's focus will be on specialists and other top-decile physicians who treat insomnia. In addition, Procter & Gamble will promote Silenor to targeted pharmacies and will provide supplemental managed care support services for Silenor. Somaxon has also granted Procter & Gamble a right of first negotiation relating to rights to develop and market Silenor as an over-the-counter medication in the U.S.

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA(TM) (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS(R) (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.

"This agreement provides clarity on the revenue stream and respective responsibilities of the parties in our ophthalmic collaboration," said Adrian Adams, President and CEO of Inspire. "We have solidified the term for potential RESTASIS(R) and follow-on product revenues and have eliminated any financial commitment for both the continued development of PROLACRIA(TM) and the co-promotion of RESTASIS(R). We are pleased to have now gained sole control over any future PROLACRIA(TM) development while retaining the right to leverage the asset as appropriate. At this time, we are not planning to proceed with clinical development of PROLACRIA(TM). Our strategy is to create shareholder value by focusing resources on our AZASITE(R) franchise and our potentially transformational denufosol tetrasodium for cystic fibrosis program."

NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), announced today that Harry F. Hixson, Jr., Ph.D. has resigned from the company's Board of Directors due to increasing executive responsibilities at Sequenom, Inc. (Nasdaq: SQNM), where he is CEO and chairman. He has served as a member of NovaBay's board of directors since January 2009.

Dr. Hixson served as chairman of the board of Sequenom since 2003. In September 2009, he became interim CEO and was appointed CEO in March 2010. In addition to his role as chairman and CEO at Sequenom he is a director of privately-held BrainCells, Inc.

About U.S. Equity News

U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.

U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.

Contact Information:
U.S. Equity News
Tel: (949) 517-2426
Email: info@usequitynews.com

Comments:
Disclaimer: User Comments do not reflect the views of US Equity News, and we are not responsible for the content of users' comments. We also reserve the right to edit or delete comments to our discretion.

---